Next 10 |
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
2023-08-08 04:32:15 ET As of August 3, RegeneRx Biopharmaceuticals ( OTCQB:RGRX ) received consents from 51.7% stockholders in favor of the proposed reverse stock split, which is a prerequisite to allowing the company to suspend its public reporting obligations and become a non-re...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 PR Newswire ROCKVILLE, Md. , April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug developmen...
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy PR Newswire ROCKVILLE, Md. , Jan. 31, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused o...
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy PR Newswire ROCKVILLE, Md. , Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug deve...
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease PR Newswire Expect ARISE-4 Trial to Begin Around 2 nd Quarter of 2023 ROCKVILLE, Md. , Oct. 24, 2022 /PRNewswire/ -- RegeneRx Bio...
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK) PR Newswire First of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md. , Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OT...
RegeneRx Issues 2022 Letter To Stockholders PR Newswire Update on Product Candidates, FDA Regulatory Strategy, Operations ROCKVILLE, Md. , Aug. 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "Regen...
News, Short Squeeze, Breakout and More Instantly...
Regenerx Biopharms Inc Company Name:
RGRX Stock Symbol:
OTCMKTS Market:
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...